Eli Kalif compensation by year
TEVA PHARMACEUTICAL INDUSTRIES Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $781,918 | $856,486 | $1,012,687 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $2,999,984 | $3,749,975 | $3,799,989 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $880,504 | $1,269,123 | $1,788,633 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $281,426 | $299,475 | $360,682 |
| Total | $4,943,832 | $6,175,059 | $6,961,991 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD DEF 14A filed March 31, 2026, accession 0001193125-26-134756, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 186,011 | $5,805,403 | — |
| RSU | 141,478 | $4,415,528 | — |
| RSU | 99,602 | $3,108,578 | — |
| RSU | 79,664 | $2,486,313 | — |
| RSU | 69,754 | $2,177,022 | — |
| PSU | 39,833 | $1,243,188 | — |
| RSU | 33,512 | $1,045,910 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments TEVA PHARMACEUTICAL INDUSTRIES discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $567,739 | $0 | — | $768,049 |
| Resignation for good reason, no change in control | $567,739 | $0 | — | $768,049 |
| Change in control and involuntary termination | $2,067,739 | $0 | — | $2,268,049 |
| Death | — | $24,011,414 | — | $24,011,414 |
| Disability | — | $24,011,414 | — | $24,011,414 |
Per the Potential Payments Upon Termination or Change in Control table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
TEVA PHARMACEUTICAL INDUSTRIES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Francis | President and Chief Executive Officer | $19,168,709 |
| Evan Lippman | Executive Vice President, Business Development | $7,222,009 |
| Eli Kalif · this page | Executive Vice President, Chief Financial Officer | $6,961,991 |
| Eric Hughes | Executive Vice President, Global R&D and Chief Medical Officer | $6,298,933 |
| Christine Fox | Executive Vice President, U.S. Commercial | $5,895,161 |
The full TEVA PHARMACEUTICAL INDUSTRIES compensation record
free company briefThis page is one person within TEVA PHARMACEUTICAL INDUSTRIES's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order TEVA PHARMACEUTICAL INDUSTRIES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TEVA PHARMACEUTICAL INDUSTRIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat